- Home
- MDGL vs QFIN Comparison
MDGL vs QFIN Comparison
Compare MDGL & QFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- QFIN
- Stock Information
- Founded
- MDGL 2011
- QFIN 2016
- Country
- MDGL United States
- QFIN China
- Employees
- MDGL N/A
- QFIN N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- QFIN Finance: Consumer Services
- Sector
- MDGL Health Care
- QFIN Finance
- Exchange
- MDGL Nasdaq
- QFIN Nasdaq
- Market Cap
- MDGL 7.4B
- QFIN 5.9B
- IPO Year
- MDGL N/A
- QFIN 2018
- Fundamental
- Price
- MDGL $308.44
- QFIN $38.25
- Analyst Decision
- MDGL Buy
- QFIN Strong Buy
- Analyst Count
- MDGL 14
- QFIN 1
- Target Price
- MDGL $347.33
- QFIN $37.50
- AVG Volume (30 Days)
- MDGL 355.8K
- QFIN 1.7M
- Earning Date
- MDGL 10-31-2024
- QFIN 11-19-2024
- Dividend Yield
- MDGL N/A
- QFIN 3.08%
- EPS Growth
- MDGL N/A
- QFIN 42.14
- EPS
- MDGL N/A
- QFIN 4.99
- Revenue
- MDGL $76,813,000.00
- QFIN $2,449,056,522.00
- Revenue This Year
- MDGL N/A
- QFIN $6.22
- Revenue Next Year
- MDGL $194.49
- QFIN $4.03
- P/E Ratio
- MDGL N/A
- QFIN $7.67
- Revenue Growth
- MDGL N/A
- QFIN 9.41
- 52 Week Low
- MDGL $168.25
- QFIN $13.71
- 52 Week High
- MDGL $368.29
- QFIN $40.31
- Technical
- Relative Strength Index (RSI)
- MDGL 51.11
- QFIN 57.44
- Support Level
- MDGL $289.80
- QFIN $37.47
- Resistance Level
- MDGL $315.09
- QFIN $40.23
- Average True Range (ATR)
- MDGL 12.44
- QFIN 1.32
- MACD
- MDGL -4.11
- QFIN -0.09
- Stochastic Oscillator
- MDGL 48.58
- QFIN 59.20
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.